296 related articles for article (PubMed ID: 18159075)
21. Adjuvant therapy of cutaneous melanoma -- current status.
Hansson J
Acta Oncol; 2006; 45(4):369-72. PubMed ID: 16760171
[No Abstract] [Full Text] [Related]
22. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
23. Molecule of the month. Elesclomol and obatoclax mesylate.
Drug News Perspect; 2008 Mar; 21(2):123-4. PubMed ID: 18389103
[No Abstract] [Full Text] [Related]
24. Adjuvant therapy for cutaneous melanoma.
Nathan FE; Mastrangelo MJ
Semin Oncol; 1995 Dec; 22(6):647-61. PubMed ID: 8539640
[No Abstract] [Full Text] [Related]
25. Azidothymidine inhibits melanoma cell growth in vitro and in vivo.
Humer J; Ferko B; Waltenberger A; Rapberger R; Pehamberger H; Muster T
Melanoma Res; 2008 Oct; 18(5):314-21. PubMed ID: 18781129
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
27. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
28. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
29. Unconventional therapies and cancer.
Bégin M; Kaegi E
CMAJ; 1999 Sep; 161(6):686-7. PubMed ID: 10513271
[No Abstract] [Full Text] [Related]
30. The ethics of early stopping rules.
Pater J; Goss P; Ingle J; Shelley W; Shepherd L
J Clin Oncol; 2005 Apr; 23(12):2862-3; author reply 2863-4. PubMed ID: 15838002
[No Abstract] [Full Text] [Related]
31. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
32. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
33. How does interferon work? Does it even matter?
Sondak VK
Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
[No Abstract] [Full Text] [Related]
34. Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Tsai KK; Daud AI
J Hematol Oncol; 2015 Oct; 8():123. PubMed ID: 26518223
[TBL] [Abstract][Full Text] [Related]
35. Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand.
Provinciali M; Pierpaoli E; Bartozzi B; Bernardini G
Anticancer Res; 2015 Oct; 35(10):5309-16. PubMed ID: 26408691
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
38. Treating metastatic melanoma: further considerations.
Legha SS
Oncology (Williston Park); 2009 May; 23(6):500, 508. PubMed ID: 19544691
[No Abstract] [Full Text] [Related]
39. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
40. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
